Clinical trial
Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease
NCT00285077 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00285077 |
|---|---|
| Title | Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease |
| Official title | Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | SR57667B |
| Enrollment | 390 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Feb 1, 2006 |
| Last update posted | Dec 23, 2008 |
| Countries | Canada, Denmark, Finland, France, Germany, South Africa, Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: